{"generic":"Erythromycin","drugs":["A\/T\/S","Akne-Mycin","Emgel","Ery-Tab","Eryc","Erycette","Eryderm","Erygel","Erythromycin"],"mono":{"0":{"id":"211718-s-0","title":"Generic Names","mono":"Erythromycin"},"1":{"id":"211718-s-1","title":"Dosing and Indications","sub":[{"id":"211718-s-1-4","title":"Adult Dosing","mono":"<ul><li>usual dosage is 250 mg every 6 hours (delayed-release capsules) or 333 mg orally every 8 hours (oral tablets); 500 mg orally every 12 hours may be used; may titrate up to 4 g per day based on severity of infection; twice daily dosing not recommended with doses greater than 1 g per day<\/li><li><b>Acne vulgaris:<\/b> (gel) apply to affected area TOPICALLY once to twice daily; or (ointment, solution and pads) twice daily after skin is thoroughly cleansed and patted dry<\/li><li><b>Allergy to penicillin - Rheumatic fever; Prophylaxis:<\/b> 250 mg ORALLY twice daily<\/li><li><b>Bacterial infection of eye:<\/b> 1 cm ribbon OPHTHALMIC ointment applied up to 6 times daily (depending on severity of infection)<\/li><li><b>Bartonellosis - HIV infection:<\/b> (bacillary angiomatosis, peliosis hepatis, bacteremia, osteomyelitis) 500 mg ORALLY 4 times daily for at least 3 months<\/li><li><b>Chancroid:<\/b> 500 mg ORALLY 3 times a day for 7 days<\/li><li><b>Chlamydial infection:<\/b> 500 mg ORALLY 4 times daily OR 666 mg ORALLY every 8 hours for at least 7 days<\/li><li><b>Diphtheria, adjunct to antitoxin; Adjunct:<\/b> 250 mg ORALLY every 6 hr or 500 mg ORALLY every 12 hr or 333 mg every 8 hr; MAX 4 g\/day, depending on type and severity of infection<\/li><li><b>Erythrasma:<\/b> 250 mg ORALLY every 6 hr or 500 mg ORALLY every 12 hr; MAX 4 g\/day or 250 mg ORALLY every 6 hr or 333 mg ORALLY every 8 hr or 500 mg ORALLY every 12 hr; MAX 4 g\/day, depending on type and severity of infection<\/li><li><b>Female gonococcal pelvic inflammatory disease:<\/b> erythromycin lactobionate 500 mg IV every 6 hr for 3 days FOLLOWED by oral erythromycin 250 mg every 6 hr or 333 mg ORALLY every 8 hr or 500 mg ORALLY every 12 hr for 7 days<\/li><li><b>Granuloma inguinale:<\/b> 500 mg ORALLY 4 times daily for at least 3 weeks and until all lesions have completely healed<\/li><li><b>Impetigo:<\/b> (Staphylococcus and Streptococcus species) 250 mg ORALLY 4 times daily for 7 days, depending on clinical response (guideline dosing)<\/li><li><b>Infection due to Entamoeba histolytica - Intestinal infectious disease:<\/b> 250 mg ORALLY every 6 hr or 500 mg ORALLY every 12 hr or 333 mg ORALLY every 8 hr for 10 to 14 days<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue (Mild to Moderate) - Soft tissue infection:<\/b> 250 mg ORALLY every 6 hr or 500 mg ORALLY every 12 hr; MAX 4 g\/day or 250 mg ORALLY every 6 hr or 333 mg ORALLY every 8 hr or 500 mg ORALLY every 12 hr; MAX 4 g\/day, depending on type and severity of infection<\/li><li><b>Legionnaires disease:<\/b> 1 to 4 g ORALLY in divided doses<\/li><li><b>Listeriosis:<\/b> 250 mg ORALLY every 6 hr or 500 mg ORALLY every 12 hr or 250 mg ORALLY every 6 hr or 333 mg ORALLY every 8 hr or 500 mg ORALLY every 12 hr; MAX 4 g\/day, depending on type and severity of infection<\/li><li><b>Lyme disease:<\/b> (alternative to first-line) 500 mg ORALLY four times daily for 14 to 21 days for early localized or early disseminated Lyme disease associated with erythema migrans, or borrelial lymphocytoma<\/li><li><b>Lymphogranuloma venereum:<\/b> 500 mg ORALLY 4 times daily for 21 days<\/li><li><b>Nongonococcal urethritis:<\/b> 500 mg ORALLY 4 times daily for 7 days (guideline dosing)  OR 666 mg ORALLY every 8 hours for at least 7 days (manufacturer dosing)<\/li><li><b>Pertussis:<\/b>  40 to 50 mg\/kg\/day ORALLY in divided doses for 5 to 14 days (manufacturer dosing)  OR 2 g\/day ORALLY in 4 divided doses for 14 days (guideline dosing)<\/li><li><b>Respiratory tract infection:<\/b> 250 mg ORALLY every 6 hr or 500 mg ORALLY every 12 hr; MAX 4 g\/day or 250 mg ORALLY every 6 hr or 333 mg ORALLY every 8 hr or 500 mg ORALLY every 12 hr; MAX 4 g\/day, depending on type and severity of infection<\/li><li><b>Syphilis:<\/b> 30 to 40 g ORALLY in divided doses over 10 to 15 days<\/li><\/ul>"},{"id":"211718-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>usual dosage 30 to 50 mg\/kg\/day orally in equally divided doses; for more severe infections, dose may be doubled; do not exceed 4 g per day<\/li><li><b>Allergy to penicillin - Rheumatic fever; Prophylaxis:<\/b> 250 mg ORALLY twice daily<\/li><li><b>Bacterial infection of eye:<\/b> 1 cm ribbon OPHTHALMIC ointment applied up to 6 times daily (depending on severity of infection)<\/li><li><b>Bartonellosis - HIV infection:<\/b> (cutaneous bacillary angiomatosis) 30 to 50 mg\/kg\/day (MAX 2 g\/day) ORALLY divided into 2 to 4 doses\/day for 3 months<\/li><li><b>Chlamydial infection:<\/b> (children less than 45 kg) 50 mg\/kg\/day ORALLY divided into 4 doses daily for 14 days<\/li><li><b>Diphtheria, adjunct to antitoxin; Adjunct:<\/b> 30 to 50 mg\/kg\/day ORALLY in equally divided doses; the dosage may be doubled for more severe infections but should not exceed 4 g\/day, depending on type and severity of infection<\/li><li><b>Erythrasma:<\/b> 30 to 50 mg\/kg\/day ORALLY divided every 6 to 8 hr; MAX 4 g\/day as base, depending on type and severity of infection<\/li><li><b>Gonococcal conjunctivitis neonatorum; Prophylaxis:<\/b> 1 cm ribbon of OPHTHALMIC ointment applied to each lower conjunctival sac; during drug shortage, 1 to 2 drops of azithromycin 1% ophthalmic solution placed in the conjunctival sac of each EYE is recommended<\/li><li><b>Impetigo:<\/b> (Staphylococcus and Streptococcus species) 40 mg\/kg\/day ORALLY in 3 or 4 divided doses for 7 days, depending on clinical response (guideline dosing)<\/li><li><b>Infection due to Entamoeba histolytica - Intestinal infectious disease:<\/b> 30 to 50 mg\/kg\/day ORALLY in divided doses over 10 to 14 days<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue (Mild to Moderate) - Soft tissue infection:<\/b> 30 to 50 mg\/kg\/day ORALLY divided every 6 to 8 hr; MAX 4 g\/day as base, depending on type and severity of infection<\/li><li><b>Legionnaires disease:<\/b> 1 to 4 g ORALLY in divided doses<\/li><li><b>Listeriosis:<\/b> 30 to 50 mg\/kg\/day ORALLY divided every 6 to 8 hr; MAX 4 g\/day as base, depending on type and severity of infection<\/li><li><b>Lyme disease:<\/b> (alternative to first-line) 12.5 mg\/kg ORALLY four times daily for 14 to 21 days for early localized or early disseminated Lyme disease associated with erythema migrans, or borrelial lymphocytoma; maximum daily dose, 2000 mg<\/li><li><b>Neonatal chlamydial conjunctivitis:<\/b> 50 mg\/kg\/day ORALLY in 4 divided doses for 14 days<\/li><li><b>Neonatal chlamydial conjunctivitis; Prophylaxis:<\/b> 1 cm ribbon of OPHTHALMIC ointment applied to each lower conjunctival sac; during drug shortage, 1 to 2 drops of azithromycin 1% ophthalmic solution placed in the conjunctival sac of each EYE is recommended<\/li><li><b>Neonatal chlamydial pneumonia:<\/b> 50 mg\/kg\/day ORALLY divided into 4 doses daily for 14 days<\/li><li><b>Pertussis:<\/b> 40 to 50 mg\/kg\/day ORALLY in divided doses for 5 to 14 days (manufacturer dosing); 14 days preferred to avoid risk of relapse; MAX 2 g\/day; use not recommended if younger than 1 month (alternative is azithromycin) (guideline dosing)<\/li><li><b>Respiratory tract infection:<\/b> 30 to 50 mg\/kg\/day ORALLY in divided doses; may double the dose for severe infections; MAX 4 g\/day<\/li><li><b>Respiratory tract infection:<\/b> (community acquired pneumonia; older than 3 months of age) 40 mg\/kg\/day ORALLY in 4 divided doses (guideline dosing)<\/li><li><b>Syphilis:<\/b> 30 to 40 g ORALLY in divided doses over 10 to 15 days<\/li><\/ul>"},{"id":"211718-s-1-6","title":"Dose Adjustments","mono":"<b>hepatic impairment:<\/b> drug may accumulate in patients with severe liver disease; no specific dosing recommendations available"},{"id":"211718-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Acne vulgaris<\/li><li>Allergy to penicillin - Rheumatic fever; Prophylaxis<\/li><li>Bacterial endocarditis; Prophylaxis<\/li><li>Bacterial infection of eye<\/li><li>Chlamydial infection<\/li><li>Diphtheria, adjunct to antitoxin; Adjunct<\/li><li>Erythrasma<\/li><li>Female gonococcal pelvic inflammatory disease<\/li><li>Gonococcal conjunctivitis neonatorum; Prophylaxis<\/li><li>Impetigo<\/li><li>Infection due to Entamoeba histolytica - Intestinal infectious disease<\/li><li>Infection of skin AND\/OR subcutaneous tissue (Mild to Moderate) - Soft tissue infection<\/li><li>Legionnaires disease<\/li><li>Listeriosis<\/li><li>Neonatal chlamydial conjunctivitis<\/li><li>Neonatal chlamydial conjunctivitis; Prophylaxis<\/li><li>Neonatal chlamydial pneumonia<\/li><li>Nongonococcal urethritis<\/li><li>Pertussis<\/li><li>Respiratory tract infection<\/li><li>Syphilis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Bartonellosis - HIV infection<\/li><li>Chancroid<\/li><li>Enteric campylobacteriosis<\/li><li>Granuloma inguinale<\/li><li>Lung disease, chronic - Ureaplasma urealyticum infection<\/li><li>Lyme disease<\/li><li>Lymphogranuloma venereum<\/li><li>Otitis media<\/li><li>Premature rupture of membranes<\/li><\/ul>"}]},"3":{"id":"211718-s-3","title":"Contraindications\/Warnings","sub":[{"id":"211718-s-3-9","title":"Contraindications","mono":"<ul><li>concomitant therapy with astemizole, cisapride, dihydroergotamine, ergotamine, pimozide, or terfenadine<\/li><li>hypersensitivity to erythromycin or any component of the product<\/li><\/ul>"},{"id":"211718-s-3-10","title":"Precautions","mono":"<ul><li>Clostridium difficile-associated diarrhea, including mild diarrhea to fatal colitis, has been reported; may occur 2 months or more after discontinuation; may need to discontinue ongoing use if suspected<\/li><li>elderly patients, especially with renal or hepatic dysfunction; increased risk of erythromycin-associated hearing loss<\/li><li>elderly patients; increased risk of QT prolongation and torsades de pointes<\/li><li>hepatic impairment; increased risk of toxicity<\/li><li>hepatotoxicity (eg, increased liver enzymes, and hepatocellular and\/or cholestatic hepatitis, with or without jaundice) has been reported<\/li><li>infantile hypertrophic pyloric stenosis (IHPS) has been reported<\/li><li>myasthenia gravis, exacerbation, and new-onset myasthenic syndrome has been reported<\/li><li>prolonged or repeated use; overgrowth of nonsusceptible bacteria or fungi (ie, superinfection) may occur; discontinue use<\/li><li>QT interval prolongation, including rare cases of arrhythmia, torsade de pointes, and fatalities, has been reported; avoid use with known QT prolongation, uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and with Class IA (quinidine, procainamide), or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents<\/li><\/ul>"},{"id":"211718-s-3-11","title":"Pregnancy Category","mono":"<ul><li>B (FDA)<\/li><li>A (AUS)<\/li><\/ul>"},{"id":"211718-s-3-12","title":"Breast Feeding","mono":"<ul><li>AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>WHO: Compatible with breastfeeding.<\/li><li>Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"4":{"id":"211718-s-4","title":"Drug Interactions","sub":[{"id":"211718-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Astemizole (probable)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (probable)<\/li><li>Colchicine (probable)<\/li><li>Dihydroergotamine (probable)<\/li><li>Dronedarone (theoretical)<\/li><li>Ergoloid Mesylates (probable)<\/li><li>Ergonovine (probable)<\/li><li>Ergotamine (probable)<\/li><li>Fluconazole (theoretical)<\/li><li>Grepafloxacin (probable)<\/li><li>Levomethadyl (probable)<\/li><li>Lomitapide (theoretical)<\/li><li>Lovastatin (probable)<\/li><li>Mesoridazine (established)<\/li><li>Methylergonovine (probable)<\/li><li>Methysergide (probable)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Simvastatin (established)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"211718-s-4-14","title":"Major","mono":"<ul><li>Acecainide (theoretical)<\/li><li>Afatinib (theoretical)<\/li><li>Ajmaline (probable)<\/li><li>Amiodarone (theoretical)<\/li><li>Amisulpride (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amoxapine (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aprindine (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Atorvastatin (probable)<\/li><li>Azimilide (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Bosutinib (theoretical)<\/li><li>Bretylium (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Carbamazepine (established)<\/li><li>Ceritinib (theoretical)<\/li><li>Cerivastatin (probable)<\/li><li>Chloral Hydrate (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Cilostazol (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clindamycin (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Daclatasvir (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Dibenzepin (theoretical)<\/li><li>Digoxin (established)<\/li><li>Diltiazem (probable)<\/li><li>Disopyramide (probable)<\/li><li>Dofetilide (probable)<\/li><li>Dolasetron (probable)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Doxepin (theoretical)<\/li><li>Doxorubicin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (theoretical)<\/li><li>Droperidol (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Encainide (theoretical)<\/li><li>Enflurane (theoretical)<\/li><li>Eplerenone (probable)<\/li><li>Escitalopram (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Everolimus (probable)<\/li><li>Fentanyl (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Formoterol (theoretical)<\/li><li>Foscarnet (theoretical)<\/li><li>Gatifloxacin (probable)<\/li><li>Gemifloxacin (probable)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (probable)<\/li><li>Haloperidol (theoretical)<\/li><li>Halothane (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydrocodone (theoretical)<\/li><li>Hydroquinidine (probable)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibrutinib (theoretical)<\/li><li>Ibutilide (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Ifosfamide (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Isoflurane (theoretical)<\/li><li>Isradipine (theoretical)<\/li><li>Itraconazole (probable)<\/li><li>Ivabradine (theoretical)<\/li><li>Ivacaftor (theoretical)<\/li><li>Ketoconazole (probable)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Lidoflazine (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Lorcainide (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Lurasidone (probable)<\/li><li>Mefloquine (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Morphine (theoretical)<\/li><li>Morphine Sulfate Liposome (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Naloxegol (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Nintedanib (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Nortriptyline (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Olaparib (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Oxycodone (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Pentamidine (theoretical)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Pirmenol (probable)<\/li><li>Pitavastatin (probable)<\/li><li>Pixantrone (theoretical)<\/li><li>Pomalidomide (theoretical)<\/li><li>Prajmaline (probable)<\/li><li>Primidone (theoretical)<\/li><li>Probucol (theoretical)<\/li><li>Procainamide (probable)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (probable)<\/li><li>Quinine (probable)<\/li><li>Ranolazine (theoretical)<\/li><li>Risperidone (theoretical)<\/li><li>Romidepsin (theoretical)<\/li><li>Sematilide (theoretical)<\/li><li>Sertindole (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Simeprevir (established)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>Spiramycin (theoretical)<\/li><li>Sulfamethoxazole (theoretical)<\/li><li>Sultopride (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tacrolimus (probable)<\/li><li>Tadalafil (theoretical)<\/li><li>Tedisamil (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telavancin (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Theophylline (established)<\/li><li>Tizanidine (theoretical)<\/li><li>Tolvaptan (theoretical)<\/li><li>Topotecan (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trabectedin (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Trifluoperazine (theoretical)<\/li><li>Trimethoprim (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Troleandomycin (probable)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vasopressin (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Verapamil (probable)<\/li><li>Vilanterol (theoretical)<\/li><li>Vinblastine (probable)<\/li><li>Vincristine (theoretical)<\/li><li>Vincristine Sulfate Liposome (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Warfarin (established)<\/li><li>Zolmitriptan (theoretical)<\/li><li>Zotepine (theoretical)<\/li><\/ul>"},{"id":"211718-s-4-15","title":"Moderate","mono":"<ul><li>Alfentanil (probable)<\/li><li>Alprazolam (probable)<\/li><li>Anisindione (probable)<\/li><li>Avanafil (probable)<\/li><li>Bexarotene (probable)<\/li><li>Bromocriptine (probable)<\/li><li>Budesonide (probable)<\/li><li>Buspirone (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Diazepam (probable)<\/li><li>Dicumarol (probable)<\/li><li>Methylprednisolone (probable)<\/li><li>Midazolam (established)<\/li><li>Phenprocoumon (probable)<\/li><li>Roflumilast (established)<\/li><li>Salmeterol (established)<\/li><li>Sildenafil (probable)<\/li><li>Sirolimus (probable)<\/li><li>Tolterodine (probable)<\/li><li>Triazolam (probable)<\/li><li>Trimetrexate (probable)<\/li><li>Valproic Acid (probable)<\/li><li>Zafirlukast (probable)<\/li><\/ul>"}]},"5":{"id":"211718-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Gastrointestinal:<\/b>Diarrhea, Loss of appetite, Nausea, Stomach cramps, Vomiting<br\/><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac dysrhythmia, Prolonged QT interval, Torsades de pointes, Ventricular arrhythmia, Ventricular tachycardia<\/li><li><b>Dermatologic:<\/b>Stevens-Johnson syndrome, Toxic epidermal necrolysis due to drug<\/li><li><b>Gastrointestinal:<\/b>Clostridium difficile colitis, Pancreatitis<\/li><li><b>Hepatic:<\/b>Cholestatic hepatitis, Hepatitis<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Seizure<\/li><li><b>Otic:<\/b>Ototoxicity<\/li><li><b>Renal:<\/b>Interstitial nephritis<\/li><\/ul>"},"6":{"id":"211718-s-6","title":"Drug Name Info","sub":{"0":{"id":"211718-s-6-17","title":"US Trade Names","mono":"<ul><li>A\/T\/S<\/li><li>Akne-Mycin<\/li><li>Emgel<\/li><li>Ery-Tab<\/li><li>Eryc<\/li><li>Erycette<\/li><li>Eryderm<\/li><li>Erygel<\/li><\/ul>"},"2":{"id":"211718-s-6-19","title":"Class","mono":"<ul><li>Antiacne<\/li><li>Antibiotic<\/li><li>Macrolide<\/li><\/ul>"},"3":{"id":"211718-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"211718-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"211718-s-7","title":"Mechanism Of Action","mono":"Erythromycin, a macrolide antibiotic, inhibits protein synthesis by binding to the 50S subunit of the bacterial ribosome in susceptible organisms.<br\/>"},"8":{"id":"211718-s-8","title":"Pharmacokinetics","sub":[{"id":"211718-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, oral: 4 hours<\/li><li>Bioavailability, oral: varies by salt<\/li><li>Effects of food: Cmax reduced by 73% and AUC reduced by 72%<\/li><\/ul>"},{"id":"211718-s-8-24","title":"Distribution","mono":"<ul><li>Vd: 40 L (Chow &amp; Ronfeld, 1975)<\/li><li>Protein binding: high<\/li><\/ul>"},{"id":"211718-s-8-25","title":"Metabolism","mono":"Liver: primary site <br\/>"},{"id":"211718-s-8-26","title":"Excretion","mono":"<ul><li>Bile: primary excretion<\/li><li>Renal: less than 5% unchanged<\/li><li>Dialysis: No (hemodialysis); No (peritoneal dialysis)<\/li><li>Hemofiltration: Yes, 37% removed<\/li><\/ul>"},{"id":"211718-s-8-27","title":"Elimination Half Life","mono":"1 to 1.5 hours <br\/>"}]},"9":{"id":"211718-s-9","title":"Administration","mono":"<ul><li><b>Oral<\/b><br\/><ul><li>may be taken with or without meals<\/li><li>(delayed-release) swallow whole; do not crush or chew<\/li><\/ul><\/li><li><b>Topical<\/b><br\/>(gel) avoid contact with eyes and all mucous membranes<br\/><\/li><\/ul>"},"10":{"id":"211718-s-10","title":"Monitoring","mono":"<ul><li>symptomatic improvement, resolution of fever or elevated WBC<\/li><li>creatine kinase and transaminase serum concentrations; in patients receiving concomitant lovastatin therapy<\/li><\/ul>"},"11":{"id":"211718-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Ophthalmic Ointment: 5 MG\/GM<\/li><li>Oral Capsule, Delayed Release: 250 MG<\/li><li>Oral Tablet: 250 MG, 500 MG<\/li><li>Oral Tablet, Delayed Release: 333 MG<\/li><li>Oral Tablet, Enteric Coated: 333 MG<\/li><li>Topical Gel\/Jelly: 2 %<\/li><li>Topical Pad: 2 %<\/li><li>Topical Solution: 2 %<\/li><\/ul><\/li><li><b>Eryc<\/b><br\/>Oral Capsule, Delayed Release: 250 MG<br\/><\/li><li><b>Erygel<\/b><br\/>Topical Gel\/Jelly: 2 %<br\/><\/li><li><b>Ery-Tab<\/b><br\/><ul><li>Oral Tablet, Delayed Release: 500 MG<\/li><li>Oral Tablet, Enteric Coated: 250 MG, 333 MG, 500 MG<\/li><\/ul><\/li><li><b>Ery<\/b><br\/>Topical Pad: 2 %<br\/><\/li><li><b>Ilotycin<\/b><br\/>Ophthalmic Ointment: 5 MG\/GM<br\/><\/li><li><b>PCE Dispertab<\/b><br\/>Oral Tablet, Delayed Release: 333 MG, 500 MG<br\/><\/li><li><b>PCE<\/b><br\/><ul><li>Oral Tablet: 500 MG<\/li><li>Oral Tablet, Delayed Release: 333 MG<\/li><\/ul><\/li><li><b>PremierPro Rx Erythromycin<\/b><br\/>Ophthalmic Ointment: 5 MG\/GM<br\/><\/li><li><b>Romycin<\/b><br\/>Ophthalmic Ointment: 5 MG\/GM<br\/><\/li><\/ul>"},"12":{"id":"211718-s-12","title":"Toxicology","sub":[{"id":"211718-s-12-31","title":"Clinical Effects","mono":"<b>MACROLIDE ANTIBIOTICS <\/b><br\/>OVERDOSE: Significant toxicity following acute overdose is uncommon.  N\/V, abdominal pain may occur.  ADVERSE EFFECTS: N\/V, abdominal pain, diarrhea most common.  Cholestasis, sensorineural hearing loss, thrombophlebitis (IV administration), ventricular dysrhythmias\/QT prolongation (IV administration) are less common. <br\/>"},{"id":"211718-s-12-32","title":"Treatment","mono":"<b>MACROLIDE ANTIBIOTICS <\/b><br\/><ul><li>Decontamination: Activated charcoal, gastric lavage.<\/li><li>Support: Therapy as indicated.<\/li><li>Abdominal discomfort: Food, milk or an antacid  may be given; most effects reverse with drug cessation<\/li><li>Monitoring of patient: Baseline ECG, cardiac monitoring as indicated. Renal and hepatic function as indicated.<\/li><\/ul>"},{"id":"211718-s-12-33","title":"Range of Toxicity","mono":"<b>MACROLIDE ANTIBIOTICS<\/b><br\/>In general, the macrolide antibiotics are of a low order toxicity. <br\/>"}]},"13":{"id":"211718-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause loss of appetite, nausea, stomach cramps, or vomiting.<\/li><li>Elderly patients are more susceptible to development of dysrhythmia and torsade de pointes.<\/li><li>Elderly patients with renal or hepatic dysfunction are at increased risk of ototoxicity.<\/li><li>Instruct patient to report severe diarrhea and consult healthcare professional prior to taking anti-diarrhea medicine.<\/li><li>Elderly patients on concomitant anticoagulant therapy should monitor for signs\/symptoms of bleeding, as drug may have additive effects.<\/li><li>Patients with a history of myasthenia gravis should report signs\/symptoms of disease exacerbation during therapy.<\/li><li>Patients using the topical gel should avoid contact with eyes and all mucous membranes.<\/li><li>Do not use with astemizole, cisapride, pimozide, terfenadine, or lovastatin.<\/li><\/ul>"}}}